| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5615373 | Journal of Clinical Lipidology | 2017 | 43 Pages |
Abstract
In this large cohort of patients with HeFH, alirocumab significantly reduced LDL-C levels. Alirocumab was generally well tolerated.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
John J.P. MD, PhD, FESC, G. Kees MD, PhD, Gisle MD, Marie T. MD, Daniel A. MD, Umesh MD, Jian MS, Pascal PhD, Michel MD, PhD,